Compare Abbott Laboratories (ABT) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs HSBC Holdings plc — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while HSBC Holdings plc trades at $95.95 (market cap $329.01B). The key difference: HSBC Holdings plc is the larger of the two by market cap, and HSBC Holdings plc pays the higher dividend (3.85%). Which is the better fit depends on your goals.
| ABT | HSBC | |
|---|---|---|
Market Cap | $166.94B | $329.01B |
Sector | Health | Technology |
52-Week High | $136.62 | $98.74 |
52-Week Low | $82.57 | $61.30 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 3.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
HSBC trades at $98.74, up 2.03% with bullish technical indicators and strong earnings momentum. The stock shows consistent earnings beats with Q1 2026 EPS of $2.20 exceeding expectations. Recent developments include strategic reviews of non-core businesses and AI partnerships with Google Cloud. Valuation metrics include a P/E of 16.32 and P/B of 1.72, while maintaining a 30.81% net income margin.
HSBC presents a balanced investment case with solid fundamentals and strategic repositioning offset by regulatory risks and market volatility. The bank's focus on core markets and AI integration supports growth potential, though recent regulatory penalties and business exits warrant monitoring. Analyst consensus leans neutral with 52.38% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
